Embedded Files
Targeting the SUMOylation system to overcome chemotherapy resistance
SUMOdulon, Inc. is developing a first-in-class pipeline of small molecule inhibitors that target key components of the SUMOylation pathway. Our approach is rooted in over a decade of peer-reviewed research conducted at The University of Texas at El Paso, and validated through rigorous preclinical laboratory studies.
What is SUMOylation?
What is SUMOylation?
SUMOylation is a cellular process in which Small Ubiquitin-like Modifier (SUMO) proteins are attached to and detached from target proteins within the cell. This process regulates critical cellular functions including DNA repair, stress response, and programmed cell death (apoptosis).
In healthy cells, SUMOylation helps maintain normal cellular function. In cancer cells, however, this system becomes dysregulated. This allows cancer cells to repair chemotherapy-induced DNA damage more efficiently, effectively neutralizing the treatment.
By targeting key enzymes in the SUMOylation pathway, SUMOdulon's compounds interrupt this resistance mechanism and restore the ability of chemotherapy to destroy cancer cells.
Our Pipeline
Our Pipeline
SUMOdulon, Inc. is developing five targeted inhibitors that disrupt key components of the SUMOylation pathway. Each compound is designed to restore cancer cell sensitivity to existing chemotherapy agents.
SUM1IN
SUM1IN
A SUMO Modifier-Targeted Inhibitor designed to block SUMO1 protein modification. Works to prevent cancer cells from activating SUMOylation-dependent survival mechanisms during chemotherapy.
SUM2IN
SUM2IN
Our lead compound. A SUMO-2/3 Modifier-Targeted Inhibitor that has demonstrated a 165-fold increase in cancer cell death in laboratory studies when combined with existing chemotherapy agents.
SAE2IN
SAE2IN
A SUMO E1 Activating Enzyme-Targeted Inhibitor that blocks the first step of the SUMOylation cascade, preventing the activation of SUMO proteins before they can be attached to target proteins.
UBC9IN
UBC9IN
A SUMO E2 Conjugating Enzyme-Targeted Inhibitor that blocks the second step of the SUMOylation cascade. Targets UBC9, the only known E2 enzyme in the SUMOylation pathway, making it a highly specific therapeutic target.
SENP1IN
SENP1IN
A SUMO Protease and Isopeptidase-Targeted Inhibitor that blocks the enzymes responsible for removing SUMO proteins from target proteins. Disrupts the balance of the SUMOylation cycle within cancer cells.
Research Validation
Research Validation
SUMOdulon, Inc.'s pipeline is built on over a decade of peer-reviewed research conducted at The University of Texas at El Paso. Our findings have been validated through rigorous preclinical laboratory studies, demonstrating the therapeutic potential of targeting the SUMOylation pathway in cancer treatment.
165x
165x
Increase in cancer cell death when SUM2IN is combined with existing chemotherapy agents
10+
10+
Years of peer-reviewed research backing SUMOdulon's scientific approach
TRL 4
TRL 4
Technology Readiness Level achieved, validated through laboratory studies funded by the 2024 Elevate Health Tech Challenge award
Supporting research report currently under review at Scientific Reports. Research results available upon request -- contact us at sumodulon@icloud.com
Current and Future Partners
Current and Future Partners
SUMOdulon, Inc. operates in collaboration with leading academic and industry partners who share our commitment to advancing cancer treatment.
Current Partner:
Current Partner:
The SUMO Laboratory
The SUMO Laboratory
Our founding research laboratory at The University of Texas at El Paso, led by Dr. German Rosas-Acosta. The scientific backbone of SUMOdulon's pipeline.
Future Partner:
Future Partner:
Sarepta Therapeutics
Sarepta Therapeutics
A leading biopharmaceutical company with expertise in the type of molecules currently used by SUMOdulon to inhibit the SUMO pathway. This partnership could greatly accelerate SUMOdulon's development efforts.
Future Partner:
Future Partner:
TLC BioSciences
TLC BioSciences
As an industry leader in the implementation of targeted delivery vehicles for small molecules, this partnership could enable the use of such vehicles to deliver SUMOdulon’s inhibitors, increasing the cancer specificity of our treatments and supporting their progress toward clinical testing.
Page updated
Google Sites
Report abuse